Your International Fund Yields 2%. This One Returned 26% and Yields 3.1%

Photo of David Beren
By David Beren Published

Quick Read

  • SCHY yields nearly 5% with consistent quarterly payments, but VXUS outperformed with a 27% total return and deeper exposure to high-growth foreign markets.

  • On a $100,000 position, SCHY delivers roughly $2,100 more in annual income than VXUS, but surrenders the semiconductor names driving VXUS's recent gains.

  • VXUS's income is unreliable for retirees. Its December 2025 payment hit $1.36 per share, then collapsed to just $0.08 in March 2026.

  • Don't wait: the analyst who called NVIDIA in 2010 just revealed his top 10 AI stocks. See the full list FREE now.

Your International Fund Yields 2%. This One Returned 26% and Yields 3.1%

© SylisiaDesign / Shutterstock.com

The Vanguard Total International Stock ETF (NASDAQ:VXUS) is the default choice for most investors who want exposure to companies outside the United States. It holds 8,807 individual holdings, tracks the market-cap-weighted global ex-US universe, and charges an expense ratio of 0.05%. That combination of breadth and near-zero cost is why VXUS sits inside so many three-fund portfolios. The question worth asking is whether a narrower, quality-and-dividend-screened fund like the Schwab International Dividend Equity ETF (NYSEARCA:SCHY) fits the reader’s actual goal better, particularly when the goal is current income rather than raw beta to foreign markets.

What VXUS Does Well, and Where It Doesn’t

The fund gives investors access to the entire non-US stock market in a single ticker. Its top holdings are anchored by Asian technology exporters, with Taiwan Semiconductor Manufacturing at 3.98%, Samsung Electronics at 2.19%, SK hynix at 1.86%, and ASML Holding at 1.39%. The top 10 holdings represent roughly 12.5% of the portfolio, which is unusually diffuse, and this is why returns tend to track the aggregate foreign benchmark closely.

The income profile is a different story. Over the trailing twelve months, the fund paid $2.19 per share, against a current price of $84.65, yielding near 2.59%. Distributions are also lumpy. The December 2025 payment was $1.3631 while the March 2026 payment was $0.0795. For an investor trying to build a predictable overseas income stream, that pattern is inconvenient.

The SCHY Alternative

The alternative screens international developed-market stocks for dividend consistency, quality, and financial strength, then weights the survivors rather than owning the whole market. Over the trailing twelve months, it paid roughly $1.11 in dividends against a current price of around $31.74, yielding near 3.43%. The distributions are also quarterly and, while they still vary seasonally, they never collapse to a token amount the way the first fund’s Q1 payment does. For a retiree pulling income, that matters more than it sounds.

The load-bearing claim in most alternative-versus-incumbent pieces is that the quality screen also delivers better total return. On current data, that claim does not hold up. The alternative returned 22.05% over the trailing twelve months and 7.84% year-to-date, while the incumbent returned 31.60% and 14.32% over the same periods. Over five years, the incumbent is up 51.91% versus the alternative at 49.63%. The incumbent trades at a PE ratio near 16, and much of the recent gain has come from the semiconductor concentration that the alternative’s screen deliberately excludes.

The Tradeoff

The dividend-yield edge for the alternative is real: roughly 80 basis points of additional current income on a TTM basis (3.43% vs. 2.59%). On a $100,000 position, that is roughly $800 more in cash distributions per year, paid on a more predictable quarterly cadence. The cost is giving up exposure to the highest-growth foreign names, which have driven most of the return spread in favor of the incumbent over the past year.

Franklin Templeton’s 2026 Global Investment Outlook flags “attractive profit growth outside the United States” and expects European equities to lead in 2026. Whether that view favors a broad index like the incumbent or a dividend-screened fund like the alternative depends on how the next cycle rewards value and payouts versus growth.

Deciding Between the Two

An investor whose international sleeve exists to smooth income should look seriously at replacing part of an incumbent position with the alternative, or holding both. An investor whose international allocation serves as a growth diversifier should stay with the incumbent.

The swap becomes clearly attractive only if a quality-dividend screen begins outperforming again, which it has not done in the current market. Selling the incumbent in a taxable account should also account for embedded capital gains, particularly for holders who bought before the recent rally.

The two funds serve different objectives: the incumbent has delivered a higher total return, and the alternative has delivered steadier cash flows. The reader’s decision reduces to which of those two outputs the international sleeve is actually supposed to produce.

Contact [email protected] for any questions or corrections.

Photo of David Beren
About the Author David Beren →

David Beren has been a Flywheel Publishing contributor since 2022. Writing for 24/7 Wall St. since 2023, David loves to write about topics of all shapes and sizes. As a technology expert, David focuses heavily on consumer electronics brands, automobiles, and general technology. He has previously written for LifeWire, formerly About.com. As a part-time freelance writer, David’s “day job” has been working on and leading social media for multiple Fortune 100 brands. David loves the flexibility of this field and its ability to reach customers exactly where they like to spend their time. Additionally, David previously published his own blog, TmoNews.com, which reached 3 million readers in its first year. In addition to freelance and social media work, David loves to spend time with his family and children and relive the glory days of video game consoles by playing any retro game console he can get his hands on.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

META Vol: 40,760,422
KMX Vol: 2,288,021
WY Vol: 6,523,553
SBAC Vol: 1,443,801
NVDA Vol: 148,249,982

Top Losing Stocks

MRNA Vol: 9,176,778
CTRA Vol: 73,319,495
CRWD Vol: 9,269,567
DDOG Vol: 5,135,556
EPAM Vol: 1,164,561